Cardiff Oncology, Inc. is a clinical-stage biotechnology firm based in San Diego, California, dedicated to developing cutting-edge, targeted therapies for the treatment of cancer. Leveraging its proprietary technology platform, the company is advancing a promising pipeline of drug candidates aimed at improving patient outcomes across various malignancies. With a strong emphasis on addressing unmet medical needs in the oncology landscape, Cardiff Oncology is strategically positioned to drive innovations that could significantly enhance treatment paradigms and the quality of life for cancer patients globally. Show more

Location: 11055 FLINTKOTE AVENUE, SAN DIEGO, CA, UNITED STATES, 92121, San Diego, CA, 92121, USA | Website: https://www.cardiffoncology.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

117.9M

52 Wk Range

$1.58 - $4.99

Previous Close

$1.62

Open

$1.66

Volume

2,205,411

Day Range

$1.58 - $1.76

Enterprise Value

58.3M

Cash

10.14M

Avg Qtr Burn

-10.83M

Insider Ownership

5.98%

Institutional Own.

34.33%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Onvansertib (monotherapy) Details Cancer, Small cell lung cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onvansertib + SOC (FOLFIRI + bevacizumab or FOLFOX + bevacizumab) Details Metastatic colorectal cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onvansertib + nanoliposomal irinotecan (Onyvide®) (PLK1) Details Cancer, Pancreatic cancer, Solid tumor/s	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onvansertib + Zytiga (abiraterone) Details Prostate cancer, Cancer, Castration-resistant prostate cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onvansertib + Paclitaxel Details Cancer, Triple-negative breast cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onvansertib (PLK1 Inhibitor) Details Chronic myelomonocytic leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onvansertib + decitabine Details Cancer, Acute myeloid leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onvansertib + Second-Line Standard-of-Care (PLK1) Details Colorectal cancer , Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.